Status: Recruiting
Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).
Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).
Participants needed: 25
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Andrés José Maria FerreriUpdated: Feb 3, 2026Locations: 1
Eligibility criteria
Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at... [+1]
Age <18 years [+2]